Business Context and Reporting Period
This Form 8-K Current Report was filed by Becton, Dickinson and Company (BD) on November 17, 2020. The report addresses significant changes in executive leadership within the Life Sciences Segment and the company's technology division.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of Executive: Patrick K. Kaltenbach, Executive Vice President and President of the Life Sciences Segment, plans to leave the company effective January 21, 2021, to pursue a leadership role in Europe.
- Succession Plan: Dave Hickey, currently President of BD's Integrated Diagnostics Solutions business unit, will succeed Mr. Kaltenbach as President of the Life Sciences Segment, effective January 1, 2021.
- Role Adjustment: Mr. Kaltenbach was previously scheduled to become Chief Technology Officer (CTO) on January 1, 2021. Due to his departure, this transition will not occur.
- Retirement Postponement: John DeFord, Executive Vice President and CTO, will postpone his previously announced retirement. He will continue to lead the company's innovation strategy and R&D pipeline until May 28, 2021, or until a successor is identified.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or management commentary regarding market conditions. The primary risk disclosed relates to the transition of leadership in the Life Sciences Segment and the CTO role, though the company has outlined a clear succession plan to mitigate disruption.
Key Facts for Investor Verification
- Confirm the effective dates for the departure of Patrick K. Kaltenbach (January 21, 2021) and the appointment of Dave Hickey (January 1, 2021).
- Verify the timeline for John DeFord's extended tenure as CTO (through May 28, 2021).
- Monitor future filings for the appointment of a permanent successor to the CTO role.